RGL-2102 / Shanghai Regenelead Therapies - LARVOL DELTA

Evaluation of the Efficacy and Safety of Injectable RGL-2102 in Patients with Severe Lower Limb Ischemia: A Randomized, Double-Blind, Parallel-Group Phase Ⅱ Clinical Trial (ChiCTR) - P2 | N=60 | Sponsor: Beijing Luhe Hospital Affiliated to Capital Medical University; Guangzhou Ruiling Pharmaceutical Co., LTD

New P2 trial • Cardiovascular

A Study to Evaluate the Efficacy and Safety of Topical RGL-2102 in Participants with Diabetic Foot Ulcers (ChiCTR) - P2/3 | N=114 | Not yet recruiting | Sponsor: West China Hospital, Sichuan University; West China Hospital, Sichuan University

New P2/3 trial

To evaluate the efficacy and safety of RGL-2102 for injection in patients with critical limb ischemia as a randomized, double-blind, multi-dose, placebo-controlled Phase II clinical trial (ChiCTR) - P2 | N=200 | Recruiting | Sponsor: Zhongshan Hospital Affiliated to Fudan University; Guangzhou Ruiling Pharmaceutical Co., LTD

New P2 trial • Cardiovascular • Peripheral Arterial Disease